News
HALO
39.26
-1.46%
-0.58
Analysts Offer Insights on Healthcare Companies: C4 Therapeutics (CCCC), Halozyme (HALO) and Eli Lilly & Co (LLY)
TipRanks · 2d ago
Weekly Report: what happened at HALO last week (0219-0223)?
Weekly Report · 2d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Immuneering (IMRX), Halozyme (HALO) and Repligen (RGEN)
TipRanks · 2d ago
Earnings Update: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
Halozyme Therapeutics, Inc. (NASDAQ:HALO) reported in line with analyst predictions. Its shares surged 11% to US$39.72 in the week since its latest yearly results. The company reported revenues of US$829m and statutory earnings per share of US $2.10. The consensus price target for the company remains at US$48.10 following the latest results.
Simply Wall St · 5d ago
JMP Securities Reiterates Market Outperform on Halozyme Therapeutics, Maintains $72 Price Target
Benzinga · 02/21 17:11
Halozyme Therapeutics Breaks Above 200-Day Moving Average - Bullish for HALO
NASDAQ · 02/21 16:36
Analysts Offer Insights on Healthcare Companies: Halozyme (HALO), NeoGenomics (NEO) and Ardelyx (ARDX)
TipRanks · 02/21 13:11
Breaking Down Halozyme Therapeutics: 7 Analysts Share Their Views
Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies. The company has an average 12-month price target of $52.43. 7 analysts have shared their evaluations of the company in the past three months. The average price target is 2.46% lower than the company's current valuation.
Benzinga · 02/21 12:00
HC Wainwright & Co. Maintains Buy on Halozyme Therapeutics, Raises Price Target to $50
Benzinga · 02/21 11:45
Halozyme Thrp: Annual report
Press release · 02/21 06:31
Analysts Offer Insights on Healthcare Companies: Bicycle Therapeutics (BCYC), GeneDx Holdings (WGS) and Halozyme (HALO)
TipRanks · 02/21 06:11
Analysts Offer Insights on Healthcare Companies: Halozyme (HALO) and AbCellera Biologics (ABCL)
TipRanks · 02/21 02:30
Compared to Estimates, Halozyme Therapeutics (HALO) Q4 Earnings: A Look at Key Metrics
NASDAQ · 02/20 22:30
Halozyme Therapeutics (HALO) Q4 Earnings Match Estimates
NASDAQ · 02/20 22:10
Halozyme Therapeutics: Q4 Earnings Insights
Halozyme Therapeutics reported its Q4 earnings on February 20, 2024. The company's revenue was up $48.54 million from the same period last year. HalozymeTherapeutics missed its earnings estimate by 1.2%. The company is expected to report its earnings on Tuesday.
Benzinga · 02/20 21:05
Halozyme Therapeutics Non-GAAP EPS of $0.82 misses by $0.01, revenue of $230.04M misses by $1.1M
Earnings News Halozyme Therapeutics Non-GAAP EPS of $.82 misses by $0.01, revenue of $230.04M misses by £1.1M in Q4. Reiterating 2024 Financial Guidance: Total revenue expected to be $915 million to $985 million.
Seeking Alpha · 02/20 21:02
More
Webull provides a variety of real-time HALO stock news. You can receive the latest news about Halozyme Thrp through multiple platforms. This information may help you make smarter investment decisions.
About HALO
Halozyme Therapeutics, Inc. is a biopharma technology platform company. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine its ENHANZE drug delivery technology with the collaborators' compounds. The Company’s proprietary enzyme, rHuPH20, is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids. The Company’s commercially approved product, Hylenex recombinant (Hylenex), and its ENHANZE partners approved products and product candidates are based on rHuPH20. It also develops, manufactures, and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technology that is designed to provide commercial or functional advantages. It has a commercial portfolio of proprietary products, including XYOSTED, TLANDO and NOCDURNA and partnered commercial products and ongoing product development programs with several pharmaceutical companies.